Fact CheckerSign in

NCT04688411Completed

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

Source: ClinicalTrials.gov · Last updated 31 Jul 2026

Brief summary (registry, in English)

The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.

Status (registry)
Completed
Study type
Interventional
Enrollment
36 (actual)
First submitted
24 Dec 2020
Start date
28 Sept 2020
Primary completion date
16 Sept 2025
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
NCT number
NCT04688411

What you commit to

  • Study type: Interventional
  • Participants enrolled: 36
  • From 28 Sept 2020 to the primary completion date, 16 Sept 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Recent hospitalizations within the past 7 days

Who the study is looking for

  • Age 12-21 years old
  • Any sickle cell disease genotype
  • On steady state of hydroxyurea for 2 months
  • Own of have access to a smartphone during the study period

Age in the registry: 12 years to 21 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Ann & Robert H. Lurie Children's Hospital of Chicago
Coordinator of this site? Confirm its status
ChicagoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.